BETA: Please send your feedback!

Gilead Sciences

NAS:GILD

Biotechnology

Market Cap

—

MEGA cap

Share Price↑↓←

(—)

YTD Return ↑↓←

—

since start of 2022

P/E Ratio

—

Corporate Values

2
1
3
—
3
1
2
4
1
—
—
3

Carbon Footprint
Pollution Prevention
Water Conservation
Data & Privacy Protection
Consumer Health, Wellness & Safety
Employee Ownership, Satisfaction, Benefits & Pay
Workplace Health and Safety
Integrity of Corporate Governance
Ethical Practices
Usage of Conflict Materials
Forced Labor
Diversity of Corporate Leadership

About

BiotechnologyFounded 1987

Gilead Sciences, Inc. is a biopharmaceutical company, which discovers, develops and commercializes therapeutics for unmet medical need. It focuses on human immunodeficiency virus and liver diseases, such as chronic hepatitis C virus infection & chronic hepatitis B virus infection, hematology & oncology, and cardiovascular & inflammation as well as respiratory diseases. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera, Atripla, Truvada, Viread, Emtriva, Tybost, Vitekta, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, Hepsera, Zydelig, Letairis, Ranexa, Lexiscan, Cayston, Tamiflu, AmBisome and Macugen. Gilead Sciences was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Headquarters

333 Lakeside Drive

Foster City, CA 94404

Executives

Name	Title	Gender
John F. Milligan, PhD	President, Chief Executive Officer & Director	Male
Robin L. Washington, MBA, CPA	Chief Financial Officer & Executive Vice President	Female
Gregg H. Alton	Executive VP-Corporate & Medical Affairs	Male
John C. Martin, PhD, MBA	Executive Chairman	Male
Norbert W. Bischofberger, PhD	Chief Scientific Officer & Executive VP-Research	Male
William A. Lee, PhD	Executive Vice President-Research	Male
Kevin B. Young	Chief Operating Officer	Male
Andrew Cheng, MD, PhD	Executive VP-Clinical Research & Development	Male
Brett A. Pletcher	Secretary, Chief Compliance Officer & Executive VP	Male
John G. McHutchison, PhD	Executive Vice President-Clinical Research	Male
Michael L. Riordan	Founder	Male
Katie L. Watson	Executive Vice President-Human Resources	Female

Mindful Investing Summary

Carbon Footprint
2N/A
Gilead Sciences performs poorly among its competitors for its carbon footprint. A company’s performance in this category is based on its success in implementing energy efficiency measures. Investments in energy efficient technology, green building and sourcing of renewable energy can all lead to cost savings and reduce the company’s contribution to climate change.
Pollution Prevention
1N/A
Gilead Sciences performs very poorly on this issue. Companies are evaluated on pollution prevention by the levels of waste (including hazardous waste) they produce and release into the environment, and can be affected by whether they develop products that can reduce exposure to pollution.
Water Conservation
3N/A
Gilead Sciences is an average performer among its peers in this category. A company’s score in this category depends on its measures to minimize water usage and impacts on stressed or drought-prone water resources.
Data & Privacy Protection
—N/A
Gilead Sciences among its peers and competitors for data privacy and protection. Companies today digitally manage vast amounts of personal information about their clients. A company’s score on this issue is based on the systems, products and procedures it has in place to minimize the risk for data and privacy breaches.
Consumer Health, Wellness & Safety
3N/A
Gilead Sciences is an average performer compared to its peers and competitors Companies in this category manage its product and safety risks.
Employee Ownership, Satisfaction, Benefits & Pay
1N/A
Gilead Sciences performs very poorly among its peers for employee satisfaction and pay. A company’s score on this issue depends on its frequency and likelihood of labor disputes as well as its practices to keep and retain talent - such as compensation, family leave, employee health care and other benefits. Employers that are rated as good to work for consistently produce higher stock returns than their peers.
Workplace Health and Safety
2N/A
Gilead Sciences performs poorly among its competitors on this issue. A company’s workplace health and safety is evaluated not only by the number of accidents and injuries in the workplace, but also by their safety policies, training procedures, and their investment in equipment that can reduce accidents.
Integrity of Corporate Governance
4N/A
Gilead Sciences performs well among its competitors on corporate governance. This score is determined by the company’s accounting practices, executive pay, board organization and ownership structure.
Ethical Practices
1N/A
Gilead Sciences performs very poorly compared to its peers and competitors. A company’s rating on this issue is based on its history of controversies related to unethical corporate behavior, such as false claims about their products, price fixing, executive misconduct, insider trading or fraudulent practices.
Usage of Conflict Materials
—N/A
Gilead Sciences among its competitors in this category. Certain products use raw materials that are commonly sourced from militias or other organizations that promote or engage in conflict in their region. To perform well in this category companies must provide adequate assurances that any of these metals used in their production are in fact from conflict-free sources.
Forced Labor
—N/A
Gilead Sciences compared to its competitors on forced labor. A company’s score on this issue depends on its use of forced labor and on its work conditions for outsourced labor.
Diversity of Corporate Leadership
3N/A
Gilead Sciences is an average performer based on its peers as well as companies in similar geographic regions. Companies are assessed on factors such as board diversity and senior management diversity. Companies performing well on this issue typically are more profitable than its peers, while companies with very poor scores typically have greater stock price volatility and lower returns on capital.

Gilead Sciences - Competitors and Related Companies

How Gilead Sciences stacks up to its peers in theBiotechnology industry or with competing business segments.

Gilead Sciences

NAS:GILD

Biotechnology

Share Price↑↓←

YTD Return ↑↓←

since start of 2022

Corporate Values

2
1
3
—
3
1
2
4
1
—
—
3

Carbon Footprint
Pollution Prevention
Water Conservation
Data & Privacy Protection
Consumer Health, Wellness & Safety
Employee Ownership, Satisfaction, Benefits & Pay
Workplace Health and Safety
Integrity of Corporate Governance
Ethical Practices
Usage of Conflict Materials
Forced Labor
Diversity of Corporate Leadership

Biogen

NAS:BIIB

Biotechnology

Share Price↑↓←

YTD Return ↑↓←

since start of 2022

Corporate Values

5
5
5
—
4
5
3
3
2
—
—
5

Carbon Footprint
Pollution Prevention
Water Conservation
Data & Privacy Protection
Consumer Health, Wellness & Safety
Employee Ownership, Satisfaction, Benefits & Pay
Workplace Health and Safety
Integrity of Corporate Governance
Ethical Practices
Usage of Conflict Materials
Forced Labor
Diversity of Corporate Leadership

Celgene

NAS:CELG

Biotechnology

Share Price↑↓←

YTD Return ↑↓←

since start of 2022

Corporate Values

3
1
3
—
3
5
5
1
5
—
—
4

Carbon Footprint
Pollution Prevention
Water Conservation
Data & Privacy Protection
Consumer Health, Wellness & Safety
Employee Ownership, Satisfaction, Benefits & Pay
Workplace Health and Safety
Integrity of Corporate Governance
Ethical Practices
Usage of Conflict Materials
Forced Labor
Diversity of Corporate Leadership

Eli Lilly

NYS:LLY

Pharmaceuticals: Major

Share Price↑↓←

YTD Return ↑↓←

since start of 2022

Corporate Values

5
2
1
—
3
4
2
1
4
—
—
4

Carbon Footprint
Pollution Prevention
Water Conservation
Data & Privacy Protection
Consumer Health, Wellness & Safety
Employee Ownership, Satisfaction, Benefits & Pay
Workplace Health and Safety
Integrity of Corporate Governance
Ethical Practices
Usage of Conflict Materials
Forced Labor
Diversity of Corporate Leadership

Johnson & Johnson

NYS:JNJ

Pharmaceuticals: Major

Share Price↑↓←

YTD Return ↑↓←

since start of 2022

Corporate Values

5
3
5
—
2
5
5
2
1
—
—
3

Carbon Footprint
Pollution Prevention
Water Conservation
Data & Privacy Protection
Consumer Health, Wellness & Safety
Employee Ownership, Satisfaction, Benefits & Pay
Workplace Health and Safety
Integrity of Corporate Governance
Ethical Practices
Usage of Conflict Materials
Forced Labor
Diversity of Corporate Leadership

Pfizer

NYS:PFE

Pharmaceuticals: Major

Share Price↑↓←

YTD Return ↑↓←

since start of 2022

Corporate Values

5
1
2
—
1
2
2
1
1
—
—
4

Carbon Footprint
Pollution Prevention
Water Conservation
Data & Privacy Protection
Consumer Health, Wellness & Safety
Employee Ownership, Satisfaction, Benefits & Pay
Workplace Health and Safety
Integrity of Corporate Governance
Ethical Practices
Usage of Conflict Materials
Forced Labor
Diversity of Corporate Leadership